Acquisition Backdrop iCardiac was acquired by ERT in 2017, placing the entity within a global clinical trial data and technology platform. This suggests potential cross-sell opportunities into ERT’s expansive customer base in pharma, biotech, and CROs seeking endpoint data, patient engagement, safety, and wearables solutions.

Small-to-Medium Scale With 11-50 employees and a focus in biotechnology research, iCardiac represents a smaller, specialized practitioner within a larger enterprise. This could mean a strategic partnership or targeted solution egress into niche projects where specialized cardiac safety and wearable data collection are needed.

End-to-End Platform ERT’s EXPERT technology platform powers trial oversight, site optimization, patient engagement, and safety/efficacy measurement. Opportunities exist to position iCardiac’s capabilities alongside EXPERT offerings to strengthen data quality, reduce trial risk, and accelerate study timelines for sponsors.

Market Velocity Historical milestones show growth in centralized data collection and imaging integration via Bioclinica, plus virtual visit capabilities. Sales potential lies in promoting integrated endpoints, at-home testing, and interoperable data flows to sponsors seeking streamlined, remote-ready trials.

Financial Signals Current revenue range indicates a lean operation with potential for scalable partnerships. Engage in joint- go-to-market strategies that leverage ERT’s global reach to expand iCardiac’s client footprint and co-sell core cardiac safety data collection and wearable monitoring solutions.